Fengling Wang
Impact in
- Drug Discovery top 2%
- Biomaterials top 5%
- Nanoparticle-Based Drug Delivery
Papers in
- Biomaterials 14
- Nanoparticle-Based Drug Delivery 14
-
- Curcumin's Biomedical Applications 5
- Co-authors
- Shaoping Ji (8 shared papers)Adil J. Nazarali (2 shared papers)陈卫东 (12 shared papers)Xiongwen Lv (5 shared papers)Liangzhi Xia (2 shared papers)Zhengwei Xie (2 shared papers)Ling Li (2 shared papers)Lijia Li (4 shared papers)
- Journals
- Drug Metabolism and Disposition (3 papers)Frontiers in Pharmacology (3 papers)International Journal of Pharmaceutics (2 papers)Journal of Inflammation Research (2 papers)Molecular Biology Reports (2 papers)
- Partner nations
- ChinaUnited StatesMacao
In The Last Decade
Fengling Wang
121 papers receiving 2.4k citations
Fengling Wang's Hit Papers
Peers
Comparison fields: 5 of 137
- Drug Discovery 19
- Biomaterials 304
- Molecular Medicine 157
- Cancer Research 144
- Hepatology 89
Countries citing papers authored by Fengling Wang
This map shows the geographic impact of Fengling Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fengling Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fengling Wang more than expected).
Fields of papers citing papers by Fengling Wang
This network shows the impact of papers produced by Fengling Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fengling Wang. The network helps show where Fengling Wang may publish in the future.
Co-authors
The 25 scholars most cited alongside Fengling Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 124 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Circular RNAs as potential biomarkers for cancer diagnosis and therapy. | 2016 | 228 |
| 2 | 2018 | 95 | |
| 3 | 2015 | 83 | |
| 4 | 2018 | 83 | |
| 5 | 2023 | 82 | |
| 6 | 2022 | 73 | |
| 7 | 2022 | 62 | |
| 8 | 2009 | 58 | |
| 9 | 2021 | 56 | |
| 10 | 2001 | 52 | |
| 11 | 2021 | 52 | |
| 12 | 2021 | 51 | |
| 13 | 2022 | 51 | |
| 14 | AI-Based Advanced Approaches and Dry Eye Disease Detection Based on Multi-Source Evidence: Cases, Applications, Issues, and Future Directions Hit paper breakdown → | 2024 | 50 |
| 15 | 2018 | 42 | |
| 16 | 2016 | 40 | |
| 17 | 2020 | 39 | |
| 18 | 2016 | 37 | |
| 19 | 2014 | 35 | |
| 20 | 2020 | 34 |
About Fengling Wang
Fengling Wang is a scholar working on Biomaterials, Molecular Medicine, Oncology, Urology and Cancer Research, having authored 124 papers that have together received 2.4k indexed citations. Recurring topics across this work include Nanoparticle-Based Drug Delivery (14 papers), Dementia and Cognitive Impairment Research (6 papers), Natural product bioactivities and synthesis (5 papers), Curcumin's Biomedical Applications (5 papers), Drug Transport and Resistance Mechanisms (5 papers), Comparative Animal Anatomy Studies (5 papers), CAR-T cell therapy research (4 papers) and Liver physiology and pathology (3 papers). The work is most often cited by research in Drug Discovery (19 citations), Biomaterials (304 citations), Molecular Medicine (157 citations), Cancer Research (144 citations) and Hepatology (89 citations). Fengling Wang has collaborated with scholars based in China, United States and Macao. Frequent co-authors include Shaoping Ji, Adil J. Nazarali, 陈卫东, Xiongwen Lv, Liangzhi Xia, Zhengwei Xie, Ling Li, Lijia Li, Yuan Huang and Weidong Chen. Their work appears in journals such as Drug Metabolism and Disposition, Frontiers in Pharmacology, International Journal of Pharmaceutics, Journal of Inflammation Research and Molecular Biology Reports.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.